The FDA recently approved the use of Apixaban for the treatment and prevention of venous thromboembolisms, which include deep vein thrombosis (DVT) and pulmonary embolisms (PE). Apixaban had previously been approved for the treatment of stroke patients, and has been found to be extremely effective following knee or hip replacement surgery.
Apixaban is an oral anticoagulant. It inhibits Factor Xa, a clotting protein in the blood. There is an increased risk of serious and potentially fatal bleeding with the use of Apixaban. Apixaban should be discontinued 24-48 hours prior to any elective surgery or invasive procedure where there is a chance of bleeding, as there is no established way to reverse the anticoagulant effects of the drug.
Often doctors and physicians recommend the use of compression socks to prevent D